Targeting mTOR for the treatment of AML. New agents and new directions - Test2 - elhamkhani - TriplyDB

Targeting mTOR for the treatment of AML. New agents and new directions

Targeting mTOR for the treatment of AML. New agents and new directions

http://www.wikidata.org/entity/Q24617223

about

The Potential of Vitamin D-Regulated Intracellular Signaling Pathways as Targets for Myeloid Leukemia Therapy Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies Rapalogs in cancer prevention: anti-aging or anticancer?You eat what you are: autophagy inhibition as a therapeutic strategy in leukemia An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment Advances in targeting signal transduction pathways mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors.Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities The Complexity of Targeting PI3K-Akt-mTOR Signalling in Human Acute Myeloid Leukaemia: The Importance of Leukemic Cell Heterogeneity, Neighbouring Mesenchymal Stem Cells and Immunocompetent Cells Autophagy is a survival mechanism of acute myelogenous leukemia precursors during dual mTORC2/mTORC1 targeting Capillary nano-immunoassay for Akt 1/2/3 and 4EBP1 phosphorylation in acute myeloid leukemia.Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.SMG1 acts as a novel potential tumor suppressor with epigenetic inactivation in acute myeloid leukemia.Selective anti-cancer agents as anti-aging drugs Mtor-Fanconi Anemia DNA Damage Repair Pathway in Cancer.In vitro Anti-Tumor Effects of Statins on Head and Neck Squamous Cell Carcinoma: A Systematic Review Dual role of hematopoietic progenitor kinase 1 (HPK1) as a positive regulator of 1α,25-dihydroxyvitamin D-induced differentiation and cell cycle arrest of AML cells and as a mediator of vitamin D resistance Using bioinformatic approaches to identify pathways targeted by human leukemogens Targeting mTOR signaling pathways and related negative feedback loops for the treatment of acute myeloid leukemia.Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer.Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine A novel AKT inhibitor, AZD5363, inhibits phosphorylation of AKT downstream molecules, and activates phosphorylation of mTOR and SMG-1 dependent on the liver cancer cell type.Mechanistic or mammalian target of rapamycin (mTOR) may determine robustness in young male mice at the cost of accelerated aging.Recent progress in genetics of aging, senescence and longevity: focusing on cancer-related genes.A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer.Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome.Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia: Yin and Yang.Butein inhibits cell proliferation and induces cell cycle arrest in acute lymphoblastic leukemia via FOXO3a/p27kip1 pathway Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells Acute myeloid leukemia: potential for new therapeutic approaches targeting mRNA translation pathways.MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells.AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications.An overview of the mTOR pathway as a target in cancer therapy.Next generation of mammalian target of rapamycin inhibitors for the treatment of cancer.Use of mTOR inhibitors in the treatment of malignancies.Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies.Eukaryotic translation initiation factor 4E as a novel therapeutic target in hematological malignancies and beyond.

P2860

Q26799596-56311FC8-EB46-43BA-9D77-B3232DEAB79E Q26829652-45C449F7-E6D3-4BEC-A2E3-14226D7D716E Q26866151-50A0DD8E-4D07-4D0C-8A1B-D523403ABB9B Q26998971-5BACDD69-58B2-4CD5-BBBC-0CB9987470FF Q27027207-257BF635-98A8-4801-83F6-B355CCB52B52 Q27686983-690E9758-9EC4-454F-A633-F5F16A6174E3 Q27851707-3AAE1D32-0D80-4CC6-B617-23CAB11D611A Q28071384-A273B148-0F49-4590-9847-7943572A504D Q28074203-0EA835F8-DC1D-410A-AA02-7A9D6037ACD6 Q33752594-4538DE4D-3FF9-4BB7-AB0C-E1696ACC88F2 Q33841929-F680BA38-043B-448E-A6E8-B5B61FEC2336 Q34260622-ED5EB56A-6CC0-4F95-9BD4-E901F69B2413 Q34307356-4AFA5619-DEEA-4252-8AB7-B548074A9B46 Q34356687-B6A922F0-7D4C-4FA0-99E6-B03079358D14 Q34392470-B8E97396-52DA-419B-833A-2C1F90511E06 Q35000084-CC99940C-34F6-4EC1-80C9-1C24F62D99AE Q35670621-5B79741F-CD0B-4EAA-8D82-3CC4FF188A47 Q35954885-1EA2E1EB-FAF9-42DF-8BD9-5242C67AD514 Q36126146-676F8205-403A-4326-B89A-DB771C033AEB Q36214081-6467A442-75ED-4DDF-A867-6C69EB2F21EF Q36299762-1AE4A555-E8E4-4B8D-9B4A-0B4C87DB3EAA Q36339232-96DF051C-4D54-4B56-8082-5F93E27124BF Q36556350-0102D121-5FAB-4CF0-BBE5-58FCB1ADEB69 Q36640327-019EDCCF-DEFC-412E-80E6-E9A5B848CB8D Q36736362-8CF5226F-E796-40D0-A0C4-B874687E466B Q36926098-174BA293-5FAC-4190-9EF0-023F12C402A2 Q36926129-006F50E3-734D-4673-A038-FDA7FF6FF7AF Q37030911-8FF88B88-5B9C-4DFA-8FD0-997926940312 Q37046021-C1E28E9D-EC70-43DE-81C0-9CA85F15971E Q37094051-DDF97AB4-2996-468A-854D-800D626E7AC9 Q37109845-28370E12-BFAB-4B42-A495-10521AB888DD Q37132224-8B2AAB6B-C9F2-48CD-A7F5-B2E154B19489 Q37364509-05330485-B218-4224-804F-E93F00DC65A6 Q37688200-703684FD-88DF-4EC8-AA60-E1491734887F Q37976243-EA77FB8C-B5D4-4E39-819E-1207BD4F761C Q38001798-A844961E-0285-4B28-B689-986D326A512F Q38094782-2676CB18-8948-431E-9D95-260A95AE41D3 Q38199196-A1D2E9D7-D0CD-4C46-BC73-2BA0BFF5BBFF Q38218128-0CC5E295-FE64-49E3-BD79-89B5273979DA Q38227377-9DCF4869-2F8E-4F3A-A240-4DD6EE52E9F7

P2860

Targeting mTOR for the treatment of AML. New agents and new directions

http://www.wikidata.org/entity/Q24617223

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Targeting mTOR for the treatment of AML. New agents and new directions

@ast

Targeting mTOR for the treatment of AML. New agents and new directions

@en

Targeting mTOR for the treatment of AML. New agents and new directions

@nl

type

label

Targeting mTOR for the treatment of AML. New agents and new directions

@ast

Targeting mTOR for the treatment of AML. New agents and new directions

@en

Targeting mTOR for the treatment of AML. New agents and new directions

@nl

prefLabel

Targeting mTOR for the treatment of AML. New agents and new directions

@ast

Targeting mTOR for the treatment of AML. New agents and new directions

@en

Targeting mTOR for the treatment of AML. New agents and new directions

@nl

P1433

Q24617223-A14C55C3-8468-4873-93D7-38C5E7E96DB4

P1476

Q24617223-C6E4341B-C513-4006-87C6-F0214F8C8B03

P2093

Q24617223-EB0BE6E3-9125-4CCC-B7CB-2FAC49E53990

Q24617223-F431D71C-5270-4345-8B44-4289E249C189

Q24617223-FA2CA4A4-F87B-4AE0-BDE9-1BC44C559F99

P275

Q24617223-91E19920-A4CB-4CAF-AB9A-A99F0ACC3F8D

P2860

Q24617223-0090334A-C824-4A52-B5C7-919DFC4CC99A

Q24617223-0650DB29-3FB1-4CDC-A266-F92829367506

Q24617223-079819E5-4D90-44A9-8950-64894EF440DF

Q24617223-0898BCD7-FBAE-4208-BD71-2E2FCC2BDC83

Q24617223-08E3003F-9107-4996-BD62-35298FFDF255

Q24617223-092DABE6-CA2E-40C4-9575-3138B73FF6FF

Q24617223-092E7D99-46E6-4CF1-A62C-B7F02A1F2AB1

Q24617223-0A24D38E-9C09-4A58-8D9E-7AEC8892B423

Q24617223-0B247724-A9E7-4D88-BB4F-B85F450E3732

Q24617223-0FD916E2-3991-4D1E-9DDB-E032B7073A4E

P304

Q24617223-3FD1FC66-17EE-4128-A7F6-251D319CCF24

P31

Q24617223-BB219441-C405-48FD-ADAA-4B7D1AFD1A25

Q24617223-D3B0791A-0B85-4019-83E5-5D76E947E5E4

P3181

Q24617223-9F60A1C2-B874-486C-A3EE-BD4A8CF9435F

P356

Q24617223-611ACA5A-600D-42C1-B0A1-9D175C670C0D

P407

Q24617223-A7A68B25-431C-4AF2-BE10-493499D0F903

P433

Q24617223-4F94C517-A047-483E-A747-8C6BD22E2B83

P478

Q24617223-326DC323-062E-427E-B6F9-C6842A4A2B96

P5008

Q24617223-CF073454-6861-4D6D-9C76-9BCDD42883FA

P577

Q24617223-971B5091-9F13-4017-AFD1-E94EC0363B49

Q24617223-AEE49120-F6A1-4E76-A651-A7166B884101

P5875

Q24617223-77177101-EFC2-46DA-B34F-50B98F2BE354

P698

Q24617223-608C3601-FAAF-45D1-B00F-1E4F58A183BB

P921

Q24617223-1DEDBEB3-A39B-49D2-B945-72D0EF198E54

Q24617223-D8B9AE97-6061-4761-A68E-C2693EFBF35D

Q24617223-FB2BE030-F4B4-4611-8DE6-47BD99E945C9

P932

Q24617223-450AA946-D86D-4321-B2DE-785ADECB494E

P3181

P356

P1433

P1476

Targeting mTOR for the treatment of AML. New agents and new directions

@en

P2093

Antonella Sassano

http://www.w3.org/2001/XMLSchema#string

Jessica K Altman

http://www.w3.org/2001/XMLSchema#string

Leonidas C Platanias

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.5 Unported

P2860

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling

mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)

Tumorigenesis suppressor Pdcd4 down-regulates mitogen-activated protein kinase kinase kinase kinase 1 expression to suppress colon carcinoma cell invasion

A novel function of the MA-3 domains in transformation and translation suppressor Pdcd4 is essential for its binding to eukaryotic translation initiation factor 4A

AKT/PKB signaling: navigating downstream

mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice

P304

510-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3196078

http://www.w3.org/2001/XMLSchema#string

P356

10.18632/ONCOTARGET.290

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2011-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51226533

http://www.w3.org/2001/XMLSchema#string

P698

21680954

http://www.w3.org/2001/XMLSchema#string

P921

acute myeloid leukemia

pharmaceutical preparation

P932

3248202

http://www.w3.org/2001/XMLSchema#string